(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 69.38%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 40.03%.
Oric Pharmaceuticals's earnings in 2026 is -$135,270,000.On average, 18 Wall Street analysts forecast ORIC's earnings for 2026 to be -$156,465,616, with the lowest ORIC earnings forecast at -$242,616,172, and the highest ORIC earnings forecast at -$124,755,666. On average, 12 Wall Street analysts forecast ORIC's earnings for 2027 to be -$168,561,364, with the lowest ORIC earnings forecast at -$197,466,502, and the highest ORIC earnings forecast at -$140,094,478.
In 2028, ORIC is forecast to generate -$169,866,380 in earnings, with the lowest earnings forecast at -$193,746,232 and the highest earnings forecast at -$150,320,352.